Meningitis B Outbreak: UK Considers Wider Vaccination After Kent Cases & Deaths

The UK’s Joint Committee on Vaccination and Immunisation (JCVI) is reviewing the case for expanding routine meningitis B vaccination following a recent outbreak in Kent, where two people have died. The review, announced after a request from Health Secretary Wes Streeting, will examine eligibility for the MenB vaccine for a broader population than currently recommended. This comes as health officials warn of potential spread beyond Kent as students travel home for the Easter holidays.

Outbreak Details and Current Response

As of Friday, March 20, 2026, the UK Health Security Agency (UKHSA) has confirmed 18 cases of group B meningococcal disease, with another 11 cases under investigation, all linked to the outbreak. The majority of cases have been traced back to the Club Chemistry nightclub in Canterbury during the first week of March and associated social networks. The nightclub has voluntarily closed its doors. NHS Kent and Medway reports having already vaccinated over 4,500 people and distributed more than 10,500 doses of antibiotics as a preventative measure. Health officials describe the speed of the outbreak as unprecedented, noting it’s the fastest-growing cluster seen in decades.

Understanding Meningitis B

Meningitis is an inflammation of the membranes surrounding the brain and spinal cord. It can be caused by several different pathogens, including bacteria, viruses, and fungi. Meningitis B, caused by Neisseria meningitidis group B, is a particularly aggressive form. Symptoms can appear rapidly and include fever, headache, stiff neck, vomiting, and sensitivity to light. Early diagnosis and treatment with antibiotics are crucial. Secretary of State Wes Streeting emphasized the importance of sticking to the facts in light of the rapidly evolving situation.

Current Vaccination Policy and the JCVI Review

Currently, the MenB vaccine (Bexsero) is routinely offered to infants in the UK as part of the national immunization schedule, having been introduced in 2015. However, a widespread catch-up campaign for older teenagers and young adults who were not eligible for the vaccine during infancy has not been implemented, due to concerns about cost-effectiveness. The JCVI previously determined that a catch-up campaign wouldn’t provide sufficient value, given that protection from the vaccine wanes over time and doesn’t prevent transmission of the bacteria.

The current outbreak has prompted a re-evaluation of this position. Dr. Michael Head, a senior research fellow at the University of Southampton, suggests that adding the MenB vaccine to routine year 9 (age 13-14) school immunizations could be a viable option. This would leverage existing school-based vaccination programs, which already include the MenACWY vaccine, designed to protect against different strains of meningococcal disease. However, Professor Andy Pollard, director of the Oxford Vaccine Group, expressed skepticism that the JCVI would recommend expanding MenB vaccination, citing budgetary constraints imposed by the Treasury.

Potential for Spread and Public Health Scenarios

Dr. Anjan Ghosh, Kent county council’s director of public health, anticipates that sporadic cases of meningitis may emerge elsewhere in the UK over the next month as students return home for the Easter break. He outlined three possible scenarios: containment within Kent, isolated cases appearing as students travel, or the emergence of a latest cluster outside of Kent. Whereas he believes the outbreak will likely sluggish down within a month, he acknowledges that it’s too early to definitively declare a peak. He stressed that the likelihood of a new outbreak stemming from these sporadic cases is “highly unlikely”.

Vaccine Effectiveness and Supply

Initial genetic analysis indicates that the Bexsero vaccine currently being used in Kent should provide protection against the specific strain of MenB responsible for the outbreak. UKHSA confirmed the strain belongs to a group of bacteria known as group B meningococci, sequence type 485 belonging to the larger clonal complex ST-41/44. Officials have also assured the public that there are sufficient vaccine supplies available, despite reports of some pharmacies experiencing temporary shortages. Health Secretary Wes Streeting has advised against individuals privately purchasing the vaccine, stating that the risk to the general public remains low.

What Happens Next: Ongoing Surveillance and Review

The JCVI review will be crucial in determining whether changes to the national vaccination policy are warranted. The committee will weigh the potential benefits of expanded vaccination against the cost-effectiveness considerations. The UKHSA will continue to closely monitor the outbreak, providing daily updates on case numbers at 9:30 am. This ongoing surveillance will help to inform the JCVI’s assessment and guide future public health interventions. The review process will involve a thorough evaluation of the available evidence, including epidemiological data, vaccine effectiveness studies, and economic modeling. The outcome of the review is expected to influence immunization strategies not only in England but potentially across the UK, as the JCVI advises all four nations.

The family of Juliette Kenny, the 18-year-classic who tragically died from the disease, is campaigning for routine access to the meningitis B vaccine for teenagers and young people, hoping to prevent further loss. Their advocacy underscores the profound impact of this outbreak and the urgent need for a comprehensive response.